
Epizyme EPZM
Epizyme Interest Expense | EPZM
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -3.97 M | 1.15 M | -25 K | 32 K | 83 K | 79 K | 59 K | -81 K | -78 K | -23 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 M | -22.4 M | -2.29 M |
Quarterly Interest Expense Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.39 M | -5.48 M | - | -5.64 M | -5.58 M | -5.48 M | -3.97 M | -1.72 M | -885 K | -48 K | 1.15 M | -15 K | -13 K | -6 K | - | -6 K | -11 K | 18 K | - | -32 K | 10 K | 4 K | - | 21 K | - | - | - | - | - | 20 K | - | 17 K | 12 K | 12 K | - | 3 K | -50 K | -39 K | - | -39 K | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 M | -5.64 M | -1.18 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-77 K | - | - | $ 8.42 M | ||
|
Merus N.V.
MRUS
|
1.06 M | - | - | $ 5.78 B | ||
|
Exicure
XCUR
|
-275 K | $ 1.09 | 3.81 % | $ 6.86 M | ||
|
Cellectis S.A.
CLLS
|
371 K | $ 0.95 | -3.3 % | $ 95.3 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 12.03 | 1.78 % | $ 3.59 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
5.26 M | $ 58.93 | 1.57 % | $ 7.88 B | ||
|
BioMarin Pharmaceutical
BMRN
|
17.3 M | $ 55.62 | -0.59 % | $ 10.7 B | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 29.48 | 0.79 % | $ 1.96 B | ||
|
Jaguar Health
JAGX
|
67 K | $ 2.36 | 15.44 % | $ 5.5 M | ||
|
Protalix BioTherapeutics
PLX
|
3.55 M | $ 2.49 | -2.35 % | $ 196 M | ||
|
uniQure N.V.
QURE
|
10.9 M | $ 21.65 | -3.5 % | $ 1.24 B | ||
|
Stoke Therapeutics
STOK
|
9 K | $ 25.41 | 1.48 % | $ 1.5 B | ||
|
Xencor
XNCR
|
-73 K | $ 29.2 | 15.95 % | $ 2.17 B | ||
|
Annexon
ANNX
|
57 K | $ 3.71 | -1.2 % | $ 575 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 1.71 | -4.21 % | $ 2.82 M | ||
|
Incyte Corporation
INCY
|
25.1 M | $ 113.3 | -2.08 % | $ 22.1 B | ||
|
Mesoblast Limited
MESO
|
21.8 M | $ 12.43 | 1.22 % | $ 15 B | ||
|
MeiraGTx Holdings plc
MGTX
|
12.2 M | $ 9.2 | -0.16 % | $ 740 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
-7.7 M | $ 516.39 | -1.44 % | $ 132 B | ||
|
Burford Capital Limited
BUR
|
99.1 M | $ 3.24 | -3.72 % | $ 710 M | ||
|
Catalyst Biosciences
CBIO
|
-1.5 M | $ 12.77 | -0.39 % | $ 1.14 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 25.47 | 1.29 % | $ 1.19 B | ||
|
Editas Medicine
EDIT
|
-2.19 M | $ 2.4 | 0.05 % | $ 213 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
11.8 M | $ 0.36 | -10.09 % | $ 26.4 K | ||
|
Fortress Biotech
FBIO
|
17.6 M | $ 1.87 | -3.11 % | $ 52.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
441 K | $ 10.12 | 0.4 % | $ 289 M | ||
|
Foghorn Therapeutics
FHTX
|
2.58 M | $ 2.04 | 2.0 % | $ 128 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
2.83 B | $ 13.76 | 4.13 % | $ 11.5 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 9.91 | 0.71 % | $ 271 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 31.74 | 1.73 % | $ 4.04 B | ||
|
Geron Corporation
GERN
|
-375 K | $ 1.15 | 2.23 % | $ 767 M | ||
|
Gossamer Bio
GOSS
|
9.29 M | $ 9.2 | -4.27 % | $ 2.1 B | ||
|
Titan Pharmaceuticals
TTNP
|
2 K | - | -3.76 % | $ 3.47 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M |